Written question asked by Baroness Ritchie of Downpatrick (Labour) on Tuesday, 1 September 2026, in the House of Lords. It was due for an answer on Tuesday, 15 September 2026. It was answered by Baroness Merron (Labour) on Friday, 18 September 2026 on behalf of the Department of Health and Social Care.
Drugs
- Question
-
To ask His Majesty's Government whether the next review of NHS England's commercial framework for new medicines will consult on changes to the process for securing indication-specific pricing agreements for multi-indication medicines.
- Answer
-
No formal assessment has been made. The next consultation on NHS England’s Commercial Framework, currently planned for 2026/27, will seek views on commercial options including indication-specific pricing.
Secondary information
- Type
- Written question
- Reference
- HL2935
- Session
- 2026-27
- Grouped for answer
- Yes
- Subjects
- Drugs
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-09-18 15:26:26 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL2935
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL2935
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL2935